Recombinant Anti-Plasminogen antibody [EPSISR18(2)] (ab174285)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPSISR18(2)] to Plasminogen
- Suitable for: WB
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-Plasminogen antibody [EPSISR18(2)]
See all Plasminogen primary antibodies -
Description
Rabbit monoclonal [EPSISR18(2)] to Plasminogen -
Host species
Rabbit -
Tested applications
Suitable for: WBmore details
Unsuitable for: IHC-P -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide within Human Plasminogen aa 650-750 (Cysteine residue). The exact sequence is proprietary.
Database link: P00747 -
Positive control
- Natural human Plasminogen protein (ab77879) can be used as a positive control in WB. Human plasma lysate
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPSISR18(2) -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab174285 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | (1) |
1/1000 - 1/5000. Predicted molecular weight: 90 kDa.
|
Notes |
---|
WB
1/1000 - 1/5000. Predicted molecular weight: 90 kDa. |
Target
-
Function
Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells.
Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo. -
Tissue specificity
Present in plasma and many other extracellular fluids. It is synthesized in the liver. -
Involvement in disease
Defects in PLG are a cause of susceptibility to thrombosis (THR) [MIM:188050]. It is a multifactorial disorder of hemostasis characterized by abnormal platelet aggregation in response to various agents and recurrent thrombi formation.
Defects in PLG are the cause of plasminogen deficiency (PLGD) [MIM:217090]. PLGD is characterized by decreased serum plasminogen activity. Two forms of the disorder are distinguished: type 1 deficiency is additionally characterized by decreased plasminogen antigen levels and clinical symptoms, whereas type 2 deficiency, also known as dysplasminogenemia, is characterized by normal, or slightly reduced antigen levels, and absence of clinical manifestations. Plasminogen deficiency type 1 results in markedly impaired extracellular fibrinolysis and chronic mucosal pseudomembranous lesions due to subepithelial fibrin deposition and inflammation. The most common clinical manifestation of type 1 deficiency is ligneous conjunctivitis in which pseudomembranes formation on the palpebral surfaces of the eye progresses to white, yellow-white, or red thick masses with a wood-like consistency that replace the normal mucosa. -
Sequence similarities
Belongs to the peptidase S1 family. Plasminogen subfamily.
Contains 5 kringle domains.
Contains 1 PAN domain.
Contains 1 peptidase S1 domain. -
Domain
Kringle domains mediate interaction with CSPG4. -
Post-translational
modificationsN-linked glycan contains N-acetyllactosamine and sialic acid. O-linked glycans consist of Gal-GalNAc disaccharide modified with up to 2 sialic acid residues (microheterogeneity).
In the presence of the inhibitor, the activation involves only cleavage after Arg-580, yielding two chains held together by two disulfide bonds. In the absence of the inhibitor, the activation involves additionally the removal of the activation peptide. -
Cellular localization
Secreted. Locates to the cell surface where it is proteolytically cleaved to produce the active plasmin. Interaction with HRG tethers it to the cell surface. - Information by UniProt
-
Database links
- Entrez Gene: 5340 Human
- Omim: 173350 Human
- SwissProt: P00747 Human
- Unigene: 143436 Human
-
Form
Cleaved into the following 5 chains: 1.Plasmin heavy chain A2.Activation peptide3.Angiostatin4.Plasmin heavy chain A, short form5. Plasmin light chain B -
Alternative names
- Plasmin antibody
- Plasmin heavy chain A antibody
- Plasmin light chain B antibody
see all
Images
-
Anti-Plasminogen antibody [EPSISR18(2)] (ab174285) at 1/1000 dilution (purified) + Human plasma lysate at 15 µg
Secondary
Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution
Predicted band size: 90 kDaBlocking and diluting buffer: 5% NFDM/TBST.
-
Anti-Plasminogen antibody [EPSISR18(2)] (ab174285) at 1/1000 dilution + Human plasma lysate at 10 µg
Secondary
Goat anti-rabbit HRP conjugated antibody at 1/500 dilution
Developed using the ECL technique.
Predicted band size: 90 kDa
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab174285 has not yet been referenced specifically in any publications.